-Advertisement-
-Advertisement-
Conference Roundup
Long-term benefits of maralixibat in PFIC demonstrated in 2-year study
Maralixibat (MRX) demonstrates significant and sustained improvements in pruritus, serum bile acids (sBA), total bilirubin (TB), and growth in patients with progressive familial intrahepatic cholestasis (PFIC) over a 2-year period, according to a study presented at The Liver Meeting 2023. The study suggests that MRX treatment contributes to overall improved...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved